Neurotransmitter Dysregulation in Parkinson's Disease: Pathophysiological Insights and Therapeutic Perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative literature review synthesizing mechanistic and pathophysiological concepts without primary data or systematic search methodology.
PubMed 41904982 · doi:10.1021/acschemneuro.5c00809
What was done
This is a narrative review synthesizing literature on the pathophysiology of Parkinson's disease. It examines striatal dopamine depletion along with dysregulation in other neurotransmitter systems—including noradrenergic, serotonergic, cholinergic, glutamatergic, and GABAergic pathways—and their interactions with alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation.
What was found
The abstract reports no numerical data or statistical findings. It qualitatively describes how dopaminergic loss in the substantia nigra disrupts basal ganglia circuitry to cause motor deficits, while non-dopaminergic neurotransmitter systems contribute to symptom heterogeneity and disease progression. It notes that current therapies primarily address dopamine deficiency without halting or reversing neurodegeneration.
Why it matters
It emphasizes that understanding and targeting multiple non-dopaminergic neurotransmitter networks is critical for developing multi-target disease-modifying therapies and improving symptom management in Parkinson's disease.
Limits
The abstract provides no primary data, quantitative results, or systematic search criteria. The discussion is limited to high-level mechanistic overview without clinical trial results or comparative outcome metrics.
Cited by
- supports Parkinson's patients experience resting tremor as well as difficulty initiating voluntary movement due to deficits in motor-control neurons.